Conclusion
The combination of iPSC and CAR technologies provides an extraordinary
opportunity to oncology and greatly facilitates cell-based therapy for
cancer patients. This system offers researchers and clinicians efficient
and safe ways of generating iPSC-derived T cells as an unlimited T-cell
source for therapeutic purposes. Although the pre-clinical and clinical
studies concerning the combination of iPSC and CAR technologies are not
sufficient, these pioneer studies that we describe here shed light on
the applicability and feasibility of off-the-shelf T cells and CAR
iPSC-derived T cells development. Off-the-shelf CAR iPSC-derived T cells
offer that a novel universal CAR-T cell is on its way to clinical use.